Loews (L) Stock

HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) has shared the findings from a phase Ib/II clinical study (AK104-IIT-018) on cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, in patients with advanced non-small cell lung cancer (NSCLC) who did not respond to previous PD-(L)1 treatments. The results were presented by Professor Han Baohui from Shanghai Chest Hospital at the 2024 Asian Conference on Lung Cancer (ACLC). The initial outcomes of the cadonilimab combination therapy for immune-resistant NSCLC were reported as positive.

On November 12, 2024, Loews Corporation (NYSE: L) announced that it will pay a quarterly dividend of $0.0625 per share of Common Stock on December 10, 2024, to shareholders who are on record as of November 27, 2024. Loews Corporation operates in various sectors, including insurance, energy, hospitality, and packaging.

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) is set to announce its financial results for the third quarter of 2024 on Monday, November 4, 2024. The company will also share comments about its earnings on its website that day.

On September 13, 2024, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM, which is the first PD-(L)1 inhibitor that can be injected under the skin. This new method allows for a subcutaneous injection that takes about seven minutes, compared to the 30-60 minutes needed for the traditional intravenous infusion. Tecentriq Hybreza will be available for all the same uses as the intravenous version for adult patients in the U.S., including various cancers like lung, liver, skin, and soft tissue cancers.

Genentech, part of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs). This is the first PD-(L)1 inhibitor that can be given as a subcutaneous injection in the U.S. The injection takes about seven minutes, which is much quicker than the usual 30-60 minutes for intravenous administration.

On September 9, 2024, Loews Corporation (NYSE: L) announced that the Delaware Court of Chancery determined there was no wrongdoing related to its 2018 purchase of minority limited partner interests in its Boardwalk Pipelines subsidiary.

On August 6, 2024, Loews Corporation (NYSE: L) announced that it will pay a quarterly dividend of $0.0625 per share of Common Stock on September 3, 2024. This payment will go to shareholders who are on record as of the end of business on August 21, 2024. Loews Corporation operates in various sectors, including insurance, energy, hospitality, and packaging.

James Tisch will step down as President and CEO of Loews Corporation on December 31, 2024, and will be replaced by Benjamin Tisch, who is currently the Senior Vice President of Corporate Development and Strategy. Following this change, James Tisch will take on the role of Chairman of the Board of Directors. Additionally, Benjamin Tisch and Alexander Tisch, the CEO of Loews Hotels & Co, will also join the Board.

Loblaw (TSX:L) and its parent company George Weston have agreed to pay $500 million to settle a class action lawsuit regarding the grocery chain's involvement in bread price-fixing. The plaintiffs alleged that between 2001 and 2015, a group of companies including Loblaws and the Weston companies, Metro, Walmart Canada, Giant Tiger and Sobeys and its owner Empire Company Limited engaged in a price-fixing conspiracy which artificially raised the prices of packaged bread.